Open Access

New ligation independent cloning vectors for expression of recombinant proteins with a self-cleaving CPD/6xHis-tag

  • Marco Biancucci1,
  • Jazel S. Dolores1, 5,
  • Jennifer Wong1, 6,
  • Sarah Grimshaw2, 3,
  • Wayne F. Anderson3, 4,
  • Karla J. F. Satchell1, 3Email author and
  • Keehwan Kwon2, 3Email author
Contributed equally
BMC Biotechnology201717:1

Received: 21 November 2016

Accepted: 9 December 2016

Published: 5 January 2017



Recombinant protein purification is a crucial step for biochemistry and structural biology fields. Rapid robust purification methods utilize various peptide or protein tags fused to the target protein for affinity purification using corresponding matrices and to enhance solubility. However, affinity/solubility-tags often need to be removed in order to conduct functional and structural studies, adding complexities to purification protocols.


In this work, the Vibrio cholerae MARTX toxin Cysteine Protease Domain (CPD) was inserted in a ligation-independent cloning (LIC) vector to create a C-terminal 6xHis-tagged inducible autoprocessing enzyme tag, called “the CPD-tag”. The pCPD and alternative pCPD/ccdB cloning vectors allow for easy insertion of DNA and expression of the target protein fused to the CPD-tag, which is removed at the end of the purification step by addition of the inexpensive small molecule inositol hexakisphosphate to induce CPD autoprocessing. This process is demonstrated using a small bacterial membrane localization domain and for high yield purification of the eukaryotic small GTPase KRas. Subsequently, pCPD was tested with 40 proteins or sub-domains selected from a high throughput crystallization pipeline.


pCPD vectors are easily used LIC compatible vectors for expression of recombinant proteins with a C-terminal CPD/6xHis-tag. Although intended only as a strategy for rapid tag removal, this pilot study revealed the CPD-tag may also increase expression and solubility of some recombinant proteins.


Self-cleavable tag Protein purification Cysteine Protein Domain Ligation-independent cloning (LIC) InsP6


Ligation-independent cloning (LIC) represents a robust and efficient cloning technique for recombinant proteins [1]. This cloning method exploits the 3’-5’ exonuclease activity of T4 DNA polymerase, which creates extended segments of complementary DNA of the amplified gene to facilitate the annealing with the target linearized vector. This procedure does not require classical endonuclease restriction enzyme digestion or in vitro ligation. LIC is suitable for high - throughput (HT) cloning platforms used to produce large numbers of proteins without considering restriction cleavage sites for each gene of interest. LIC is often used for rapid insertion of PCR products where HT cloning for recombinant protein production plays a fundamental role for the characterization of hundreds of proteins [2, 3].

Fusion tags play significant roles in enhancement of expression and solubility, and purification of target proteins. A hexahistidine tag (6xHis-tag) is one of the most frequently used fusion tags for affinity purification of recombinant proteins. Besides the 6xHis-tag, large soluble affinity tags, such as glutathione S-transferase (GST), maltose-binding protein (MBP), thioredoxin, the transcription termination anti-termination factor NusA or small ubiquitin-like modifier (SUMO) are often used to increase the solubility of recombinant proteins [4]. However, these affinity/solubility tags have to be removed after purification in order to conduct functional studies or crystallization [5]. Although large soluble tags enhance soluble expression of recombinant proteins, sometimes they cause misfolded and non-functional target proteins. The much smaller 6xHis-tag is a frequently used peptide tag for affinity purification, but it has been reported that the highly-charged tag can negatively affect protein crystallization and/or functional characterization [6, 7].

In order to remove any fusion tag, a protease cleavage site is frequently incorporated at the junction between the target protein and the affinity/solubility tag. Proteases commonly used to specifically cleave fusion tags include thrombin, SUMO protease, Factor X, and Tobacco Etch Mosaic Virus (TEV) protease. The efficiency of proteolytic processing can sometimes be complicated by steric hindrance or by unfavorable residues close to the cleavage site. Additionally, large-scale protein production can require a relatively large amount of the protease, which may limit the final protein yield and significantly increase the purification cost. Overall, affinity/solubility-tag removal adds another layer of complexity and expense to any purification process.

In the last decade, several self-cleaving tags have been developed. These special fusion tags possess an inducible activity, which can be triggered upon binding small molecules or conformational changes induced by particular buffer conditions. Shen A. et al. [8] demonstrated that the 6xHis-tagged Cysteine Protein Domain (CPD) of Vibrio cholerae could be fused at the C-terminus of the target protein and be used as self-cleavage fusion system. This technology was also developed independently by Northwestern University [9, 10]. CPD is a highly conserved domain of the large V. cholerae Multifunctional-Autoprocessing Repeats-in-Toxin (MARTX) toxin [11]. Once translocated by the toxin into the eukaryotic cytosol, the CPD is activated to autoproteolyze the toxin by inositol hexakisphosphate (InsP6), releasing several cytotoxic effector domains [11]. CPD cleaves after leucine residues located in accessible loops, which are able to occupy the hydrophobic pocket of S1 site [12, 13]. Although, only a leucine residue is strictly required for CPD autoprocessing, leucine residues located between small residues are preferred substrates [12, 13]. Since InsP6 is absent in bacteria cells, self-cleaving CPD fusion systems have been used as versatile tool for expression and purification of several proteins [1214]. Moreover, the 6xHis-tagged CPD was demonstrated to improve expression, solubility, and stability of fusion proteins although the vectors used standard restriction enzyme cloning [8].

In this work, we report a new vector designated pCPD that incorporate sequences for a C-terminal 6xHis-tagged CPD (the CPD-tag) in-frame with a LIC site. We successfully tested two different self-cleaving CPD fusion proteins and compared the same proteins purified with a conventional TEV protease-cleavable 6xHis-tag. Additionally, pCPD was further modified by the insertion of a coupled cell division B (ccdB) cassette as a negative selection marker to create a vector more suitable for vector preparation and high throughput LIC. The pCPD/ccdB vector was used for HT cloning and demonstrated to improve success rates for both expression and solubility after removing the CPD-tag from recombinant proteins derived from a HT pipeline.


Enzymes and reagents

Restriction enzymes and Gibson Assembly® cloning reagents were obtained from New England Biolabs and polymerases were obtained from Life Technologies. TOP10 competent cells and InsP6 (also known as phytic acid) were obtained from Sigma-Aldrich. Other common chemicals, antibiotics, and growth media components were from Sigma-Aldrich or Thermo Fisher.

Bacterial expression vectors for production of recombinant proteins pMCSG7, pMCSG53, and pMCSG58 were obtained from Dr. Andrzej Joachimiak of the Midwest Center for Structural Genomics (MCSG). The vector pMCSG7 consists of a LIC site and encodes for an N-terminal TEV cleavable 6xHis-tagged protein [15]. The vector pMCSG53 is an upgraded version of pMCSG7 that also carries the rare codon tRNA genes argU and ileX [16]. The vector pMCSG58 is similar to pMCSG53 except it encodes for a C-terminal 6xHis-tagged protein [16]. Proteins were expressed in kanamycin-resistant BL21(DE3)MAGIC E. coli strain. The pMagic plasmid also provides a second copy of the rare codon tRNA gene argU ([17] and A. Joachimiak, personal communication).

New vectors for expression of CPD fusion proteins

Insertion of CPD into of pMCSG58 vector

DNA corresponding to coding sequence for amino acids L3428-G3637 of the V. cholerae rtxA gene (vc1451, geneID 2613957) was amplified from purified V. cholerae N16961 chromosomal DNA using Pfx50 DNA polymerase, forward primer 5’-CTTTAAGAAGGAGTCTCTCCCGGGGCAGCATTAGCGGATGG-3’ and reverse primer 5’-GATGATGATGGTGGTGAGCCCCACCTTGCGCG-3’. The vector pMCSG58 was digested with SmaI restriction enzyme and purified. 3 pmol of PCR product and 1 pmol of linearized vector were incubated with Gibson Assembly® master mix for 1 h at 50°C [18]. 1 μl of the Gibson cloning reaction was transformed into TOP10 electro-competent cells. The final plasmid pCPD was confirmed to be accurate by DNA sequencing.

Incorporation of ccdB/Cm R cassette

pCPD was modified by incorporating ccdB cassette at the cloning site to prepare pCPD/ccdB for a HT LIC platform. The cassette of ccdB and Cm R (chloramphenicol resistant gene cat) in pDONR221 was amplified by polymerase chain reaction using primers, 5’-TTAACTTTAAGAAGGAGTCTCTCCCGGG CTTCATCTGGATTTTCAGC’ and 5’-TTTTTCCATCCGCTAATGCTGCCCCGGG TTATCGAGATTTTCAGGAGCTAA-3’. The 5’-end sequences of the oligonucleotides are pCPD vector specific, the 3’-end sequences are ccdB/Cm R cassette specific. The SmaI cleavage sequence (CCCGGG) was incorporated into the center of the oligonucleotides. The vector pCPD was digested with SmaI. Both amplified ccdB/Cm R cassette and digested vector were gel-purified. 20 μl Gibson assembly® reaction with 30 fmol purified insert and vector backbone was performed as previously reported [18]. 20 μl of assembly reaction was transformed into ccdB survival TM T1 Phage-resistant E. coli. Transformants were plated on LB-agar containing 100 μg/mL ampicillin and 25 μg/mL chloramphenicol. Selected transformants were grown in 2xYT with antibiotics for plasmid preparation. The final plasmid pCPD/ccdB was confirmed by DNA sequencing.

Cloning, expression, and purification of MLDVv

DNA sequences corresponding to the membrane localization domain (MLD, NP_759056.1, amino acids Q3591-L3674) was amplified from purified V. vulnificus CMCP6 chromosomal DNA using forward primer 5’-GTCTCTCCCATGCAAATCTTTACGGTGCAAGAGCT-3’ and reverse primer 5’-TGCTGCCCCCAACGCACTGGTGACCTGCT-3’ and the products were cloned into SmaI-digested pCPD by LIC [1]. The plasmid was confirmed to be accurate by DNA sequencing and then transformed into E. coli BL21(DE3)/MAGIC. Culture was grown in Terrific Broth supplemented with 100 μg/mL ampicillin and 30 μg/mL of kanamycin at 37 °C until OD600 = 0.8 and then induced with 1 mM isopropyl-β-D-thiogalactoside (IPTG) at 25 °C for ≈ 18 h. Bacteria were harvested by centrifugation, re-suspended in buffer A1 (10 mM Tris pH 8.3, 500 mM NaCl, 0.1% Triton X-100, 1 mg/ml lysozyme, 5 mM β-mercaptoethanol (BMe) and lysed by sonication. After centrifugation at 30,000xg for 30 min, the soluble lysate was incubated with Ni-NTA resin (GE Healthcare) for 30 min at 4 °C. The Ni-NTA resin was recovered onto a gravity column and washed with buffer B1 (10 mM Tris pH 7.5, 500 mM NaCl, 50 mM imidazole) followed by elution in the same buffer with 500 mM imidazole (buffer C1). Protein was exchanged into buffer A1 (without Triton X-100) using a PD10 desalting column (GE Healthcare). The protein solution was incubated with 100 μM InsP6 for 1 h at 25 °C under gentle agitation and then loaded again onto the gravity column containing Ni-NTA (GE Healthcare), the flow through fraction containing the MLD was collected. Purified proteins were analyzed by SDS-PAGE.

KRas expression and functional characterization

Cloning, expression, and purification KRas

KRas full-length (fl) and KRas catalytic domain (residues 1–169) were amplified by PCR from a plasmid template containing the full-length KRas gene [19]. In order to insert KRas-fl and KRas1–169 into pMCSG7 and pCPD, three different set of primers were designed and used: KRas-fl-pCPD-FWD 5’-CTTTAAGAAGGAGTCTCTCCCATGACTGAATATAAACTTGTGGTAGTTGGAGCTGG-3’ - KRas-fl-pCPD-REV 5’-CCGCTAATGCTGCCCCCATAATTACACACTTTGTCTTTGACTTCTTTTTCTTC-3’; KRas1–169-pMCSG7-FWD 5’-CCTGTACTTCCAATCCAATGCTATGACTGAATATAAACTTGTGGTAGTTGG-3’ - KRas1–169-pMCSG7-REV 5’-CCGTTATCCACTTCCAATTTACTACTTTTCTTTATGTTTTCGAATTTCTCGAACTAATG-3’; KRas1–169-pCPD-FWD 5’-CTTTAAGAAGGAGTCTCTCCCATGACTGAATATAAACTT GTGGTAGTTGG-3’ - KRas1–169-pCPD-REV 5’-CCGCTAATGCTGCCCCCTTTTCTTTATGTTTTCGAATTTCTCGAACTAATG-3’) for Gibson Assembly® cloning method. The vectors pMCSG7 and pCPD were digested with SspI or SmaI, respectively. PCR products (KRas1–169-pMCSG7, KRas-fl-pCPD and KRas1–169-pCPD) and linearized vectors were gel-purified. 10 μl of Gibson Assembly® master mix, 1 pmol pMCSG7 or pCPD linearized vectors and 3 pmol the respective PCR products were incubated for 1 h at 50 °C. 1 μl of the Gibson Assembly® reaction mix was transformed into TOP10 electro-competent cells. Plasmids were confirmed to be accurate by DNA sequencing and then transformed into E. coli BL21(DE3)/MAGIC. All KRas fl proteins were expressed as described above for MLD. KRas1–169-CPD and KRas1–169 were purified as described here. Bacteria were harvested by centrifugation, re-suspended in buffer A1 (50 mM Tris pH 8.3, 500 mM NaCl, 10 mM MgCl2, 0.1% Triton X-100, 5 mM BMe) and lysed by sonication. After centrifugation at 30,000xg for 30 min, the soluble lysates were loaded onto a 5-ml HisTrap column using the ÄKTA Purifier system (GE Healthcare). The column was washed with buffer B1 (10 mM Tris pH 7.5, 500 mM NaCl, 10 mM MgCl2, 50 mM imidazole) followed by elution in the same buffer with 500 mM imidazole (buffer C1). Proteins were further purified by size-exclusion chromatography (SEC) (Superdex 200 (26/60), GE Healthcare) in buffer D1 (10 mM Tris–HCl pH 7.5, 500 mM NaCl, 10 mM MgCl2, 5 mM BMe). The 6xHis-tag of KRas1–169 expressed from pMCSG7 was cleaved overnight with TEV protease and further purified by removal of uncleaved protein using a HisTrap column (GE Healthcare). The KRas1–169-CPD fusion protein was incubated with 100 μM InsP6 (Sigma Aldrich) for 1 h at 25 °C under gentle agitation. The protein sample treated with InsP6 was loaded onto a HisTrap column (GE Healthcare) and the flow through fraction containing KRas1–169-GAAL was collected. Purified proteins were analyzed by SDS-PAGE. The Coomassie stained gel was scanned and band intensity of each recombinant protein was quantified using the NIH ImageJ v1.49 software.

Cloning, expression, and purification of GAP-334

Sequence of GAP-334 (residues 712–1046) was amplified from a plasmid containing the p120 sequence found in the KRAS Entry and RAS Pathway Clone Collection (Leidos Biomedical Research, Inc.) using the following primers: FWD 5’-CCTGTACTTCCAATCCAATGCTATGGAAAAAATCATGCCAGAAGAAGAG-3’ and REV 5’-CCGTTATCCACTTCCAATTTACCTGACATCATTGGTTTTTGTATAC-3’. The PCR product was cloned into pMCSG7 as described for KRas1–169 above. Plasmids were confirmed to be accurate by DNA sequencing and then transformed into E. coli BL21(DE3)/MAGIC. GAP-334 protein was expressed and purified as described above for KRas1–169, except all buffers were adjusted to pH 8.3. Purified protein was analyzed by SDS-PAGE.

KRas Single-turnover GTP hydrolysis

Single-turnover GTP hydrolysis analysis was performed as previously described [20]. All buffers were made phosphate-free by dialysis with 2 U of nucleoside phosphorylase and 0.5 mM of inosine. Briefly, for intrinsic hydrolysis, 20 μM of Ras was used. For GAP-mediated hydrolysis GAP-334 was used at final concentration of 0.2 μM and 0.1 μM, in order to have a GAP:Ras ratio of 1:100 and 1:200 respectively. FlippiU purified from vector pRSET FLIPPi-5u (Addgene) as previously described [21] was used to detect in real-time the amount of inorganic phosphate released in solution by the GTP hydrolysis [21]. The ratio of fluorescence emission 480/530 nm was measured with an excitation of 435 nm on SpectraMax M3 (Molecular Devices). Data were converted to phosphate concentration using a standard curve. Data were fit in GraphPad Prism 6.0 to a one-phase exponential association curve to determine the k obs. All reactions were performed in triplicate.

Compare HT expression and protein solubility

PCR amplification of target ORFs and cloning into two vectors

Forty protein targets representing the next forty proteins or subdomains in the HT structural determination pipeline of the CSGID were selected. Two LIC expression vectors, pCPD/ccdB and pMCSG53/ccdB were used for protein expression and target open reading frames (ORFs) were amplified by PCR. In order to clone into pCPD/ccdB vector, PCR primers were designed such that gene specific sequences were followed by vector specific regions 5’-GTCTCTCCC, and 5’-TGCTGCCCC in forward primer and reverse primer, respectively. For pMCSG53/ccdB, vector specific region sequences, 5’-TACTTCCAATCCAATGCG and 5’-TTATCCACTTCCAATG were added to forward and reverse primers. PCR amplification of ORFs was performed using a standard PCR condition.

The PCR products for pCPD were treated with T4 DNA polymerase in the presence of dTTP. The LIC vector, pCPD/ccdB was digested with SmaI (5U/μL DNA) to remove ccdB and treated with T4 DNA polymerase in the presence of dATP, After T4 DNA polymerase treatment, 0.02 pmol of vector DNA and 0.04 pmol of insert DNA were mixed and annealed at 22 °C for 30 min as previously described [15]. 2 μL of the reactant was transformed into 25 μL of chemically competent E. coli DH5α using the heat shock method.

Cloning into pMCSG53/ccdB used a modified method of cloning for pMCSG7 as previously described [15]. PCR product and vector backbone from linearized pMCSG53/ccdB were treated with T4 DNA polymerase in the presence of dCTP and dGTP, respectively. Annealing of vector backbone and PCR and transformation into DH5α were performed as described above for cloning targets into pCPD.

Protein Expression Screening and Cleavage

The forty plasmids for each vector system were transformed to E. coli BL21(DE3)/MAGIC. Cells were grown in 1 mL 2xYT in a 96-well block at 37 °C at 900 rpm using a multitron shaker. Once cells reached an OD600 = 0.8, gene expression was induced by adding IPTG to a final concentration of 1 mM and incubating at 25 °C for 18–20 h. Cells were pelleted by centrifugation at 2,200xg for 30 min at 4 °C and stored at −80 °C. Cell pellets were thawed and resuspended in lysis buffer (50 mM Tris–HCl, 5 mM imidazole, 300 mM NaCl, 1mM dithiothreitol (DTT) pH 7.8 at 4 °C) and lysed by adding PopCulture Reagent (EMD-Novagen). Aliquots of cell lysates were transferred to a new 96-well plate and the remaining were centrifuged at 2,200xg for 1 h to separate the soluble fraction. The soluble fractions were transferred to a 96-well plate. Whole lysate and supernatant fractions were processed on the LabChip GXII (Perkin Elmer, Waltham, MA) to examine expression and solubility level of N-terminal 6xHis-tag fused target proteins. C-terminal CPD-tag fused recombinant proteins were purified using Ni-NTA agarose resin in a 96-well block as previously described [22]. The recombinant proteins were eluted in 200 μL elution buffer (50 mM Tris–HCl, 200 mM imidazole, 300 mM NaCl, 1mM DTT pH 7.8 at 4 °C). The purified proteins were exchanged into a lysis buffer and concentrated using a 96-well Multiscreen filter plate with an Ultracel-10 membrane (EMD-Millipore, Billerica, MA). The CPD-tag of the recombinant proteins were activated by adding InsP6 to a final concentration of 100 μM and incubating for 2 h at room temperature. The cleaved 6xHis-tagged CPD was removed by adding 25 μL Ni-NTA agarose resin and incubated for 30 min at 4 °C. The target proteins were transferred into a new 96-well plate. Whole lysates and supernatants and purified and cleaved proteins were examined HT capillary electrophoresis (LabChip GXII) and/or NuPAGE with Coomassie blue staining (Additional file 1: Figure S1). As previously reported [23], the level of expression and solubility of recombinant proteins were scored as four categories: 0 (undetectable), 1 (low), 2 (medium), and 3 (high) (Additional file 2). The scale is approximately, 0: <2%, 1: 2-10%, 2: 5–10%, 3: >10%. The purity percentage was obtained directly from LabChip HT software.

Results and discussion

Design and development of self-cleavage LIC/CPD fusion system

The cpd DNA sequence was amplified with LIC primers specific for SmaI-digested the vector pMCSG58 [16], which was used as backbone for the creation of the LIC/CPD fusion system (Fig. 1a). pMCSG58 is a bacterial expression vector that encodes a C-terminal 6xHis-tag and additionally contains a LIC site and argU and ileX genes for rare codon tRNAs [16]. The forward primer was designed with extra nucleotides in order to restore the LIC site and SmaI restriction site after the insertion of cpd sequences. In the newly created vector pCPD, the sequence for the LIC site is in frame with codons for the CPD followed by a 6xHis-tag (Fig. 1b). This vector pCPD is thus designed to express recombinant proteins with a CPD-tag at the C-terminus both to mimic its natural activity and because it is currently unknown whether N-terminal CPD-tag can efficiently autoprocess its own C-terminus [12]. DNA sequences of a target protein can be cloned into pCPD by LIC with T4 DNA polymerase or by Gibson Assembly® [18] (Fig. 1c) or other commercial direct cloning methods. The protein fusion resulting from expression of DNA sequences cloned into pCPD will have four additional residues Gly-Ala-Ala-Leu at the junction between the target protein and the CPD (Fig. 1c). These four residues represent the encoded sequence for LIC and provide a Leu and a flexible linker for insertion into the CPD active site. The addition of InsP6 to a purified fusion protein will trigger activation of CPD proteolytic activity and the recombinant protein will be cleaved after the Leu (Fig. 1c).
Fig. 1

Design and cloning strategy of pCPD. a Sequence of LIC site in pMCSG58; b Sequence of LIC site in pCPD; c Molecular cloning strategy for the pCPD vector. After SmaI digestion linearized pCPD is treated with T4 polymerase and dATP. Target protein is amplified by PCR using LIC primers. PCR product is treated with T4 polymerase and dTTP. Both vector and PCR product are mixed for annealing and then transformed into competent cells

The C-terminal CPD-tag was previously proposed as a rapid single-step purification strategy for the 6xHis-tag removal while still bound on the initial column [8]. However, many biochemical studies require recombinant proteins with high purity and integrity. Thus, we sought to develop a purification protocol using a two-step removal/purification process rather than single step. For high efficiency of cleavage, the uncleaved CPD fusion protein is first eluted from Ni-NTA column followed by a second desalting or size exclusion step to remove imidazole and protein aggregates from the CPD protein-fusion (Fig. 2a). The CPD fusion-protein is then treated in solution with InsP6, triggering CPD autoprocessing and thereby releasing the target protein. The cleaved CPD-tag is separated from the target protein by an additional passage over a Ni-NTA column (Fig. 2a).
Fig. 2

Purification strategy of autoprocessing CPD fusion-tag. a Self-cleaving CPD-fusion protein purification; b Purification of MLD. Marker (M), Total proteins (Tot), Soluble proteins (Sol), Washing step with 50 mM imidazole (W), Elution step with 500 mM imidazole containing MLD-CPD (E1), 1 h incubation with InsP6 (InsP6), First flow-through fraction containing MLD (FT1), Second flow-through fraction (FT2), Elution step with 500 mM imidazole containing CPD (E2), and previously purified MLD (MLD)

In order to test the feasibility of the system to purify small proteins, purification of the 83 amino acid MLD from the V. vulnificus MARTX toxin Ras/Rap1 Specific Protease (RRSP) [19, 24] was conducted. MLD is a 10 kDa protein while CPD is 27 kDa and as shown in the Fig. 2b, the fusion protein ran at the expected molecular weight on an SDS-polyacrylamide gel. Imidazole in the elution buffer was removed using a desalting column and the protein solution was adjusted to 100 μM InsP6. After an hour, the fusion protein was completely cleaved. The MLD was separated from the CPD-tag by incubating the protein solution with Ni-NTA resin and collecting the unbound fraction (Fig. 2b). As shown in the Fig. 2b, the MLD cleaved by CPD (MLDGAAL) ran at the expected molecular weight.

Using pCPD vector for expression of highly soluble KRas

To test for successful purification of a eukaryotic protein, Ras, a human oncoprotein involved in the regulation of cell proliferation, differentiation and survival [25, 26]. Although recombinant Ras proteins are well expressed in E. coli, the final purification yield of the isoform KRas is low due to the formation of inclusion bodies [27]. To test whether our self-cleavage system could improve KRas yield, we cloned the full-length KRAS gene sequence or the sequence corresponding to the catalytic domain (KRas1–169) into pCPD. For comparison to an alternative expression system, the genes were also cloned into pMCSG7, which was previously used for KRas production [19]. The vector pMCSG7 has the LIC site and encodes for an N-terminal 6xHis-tag and TEV cleavage site [15].

Although the protein expression for each construct was similar, KRas-CPD and KRas1–169-CPD were highly soluble (Fig. 3a and b). In particular, KRas1–169-CPD was three times more soluble than N-terminal 6xHis-tagged KRas1–169 (6xHis-TEV-KRas) expressed from the vector pMCSG7 and KRas-CPD was four times more soluble than N-terminal 6xHis-tagged KRas (Fig. 3b). KRas1–169-CPD and 6xHis-TEV-KRas1–169 were each purified to quantify the final purification yield and to check for function in a GTPase activity assay. Lysates containing each protein were loaded onto a Ni-NTA column and eluted in imidazole buffer as the first step of purification. Subsequently, KRas1–169-CPD and 6xHis-TEV-KRas1–169 were subjected to SEC. Elution fractions containing KRas1–169-CPD were pooled and treated with 100 μM InsP6. After 10 min, 30 min and 1 h, protein samples were collected to check CPD autoprocessing. After 1 h, the protein fusion was cleaved and the solution containing KRas1–169-GAAL and the CPD-tag were passaged across a Ni-NTA column (Fig. 3c). KRas1–169-GAAL was recovered into the flow-through fraction with a final yield of 35 mg/L. Separately, purified 6xHis-TEV-KRas1–169 was incubated overnight with TEV protease, then the protein solution was loaded onto Ni-NTA column and the flow-through fraction was collected, the final protein yield was 11 mg/L. Both KRas1–169 and KRas1–169-GAAL were separated by SDS-PAGE showing high purity and expected similar molecular weight (Fig. 3d).
Fig. 3

Expression and purification of KRas with pCPD and pMCSG7. a-b Expression and solubility of KRas1–169 and KRas fl. The amount of expressed and soluble proteins were analyzed by SDS-PAGE and measured with ImageJ software. Bars are the average of three independent biological replicates; c Marker (M), Total proteins (Tot), Soluble proteins (Sol), Elution step with 500 mM imidazole containing KRas1–169 -CPD (El), protein concentration step (C), SEC step (SEC), incubation time with InsP6, 10, 30 and 60 min respectively (10’-30’-60’), Flow-through fraction containing KRas1–169 -GAAL (FT); d SDS-PAGE of KRas1–169 and KRas1–169 –GAAL; e-f Intrinsic and GAP mediated single-turnover GTP hydrolysis for KRas1–169 and KRas1–169 –GAAL. GAP-334 was used at two different molar ratios of 1:100 and 1:200 (GAP:KRas). Each curve and bar represent the average of three independent biological replicates

In order to compare the catalytic activities of the two different KRas proteins, GTPase activity was performed using FlippiU as a protein sensor for inorganic phosphate released in solution (Fig. 3f). KRas1–169 and KRas1–169-GAAL showed the same magnitude of intrinsic and GAP-mediated GTP hydrolysis activities, suggesting that there were no functional differences between the proteins.

Developing pCPD with a ccdB cassette for HT cloning

LIC vectors are usually prepared by restriction digestion and agarose-gel excision. Although the gel purification decreases background transformation after LIC, the digested vector is difficult to separate from the relaxed undigested vector. Therefore, even after agarose-gel purification, there is potentially still contamination with undigested vector, which can decrease the number of plasmids containing the target gene inserted, reducing the success rate in the HT cloning platform.

In order to improve cloning efficiency for the purpose of HT cloning, the vector pCPD was further modified by insertion of the ccdB gene, which encodes for a cytotoxin that targets DNA gyrase [28] (Fig. 4). The ccdB gene then acts as a negative selection marker, because transformed cells with incomplete or undigested vector will not survive after LIC due to the presence of ccdB [2931]. Thus, the advantage of the ccdB insertion is that only fully digested plasmids that have successfully incorporated the target gene insert are transformable. To insert ccdB, pCPD was digested with SmaI, and the PCR amplified 1823 bp ccdB and chloramphenicol resistance gene cassette (ccdB/Cm R ) were ligated into the site. In order to avoid loss of the LIC site, two SmaI sites were incorporated into the PCR primers, such that SmaI digestion of the final pCPD/ccdB vector is identical to that from unmodified pCPD when linearized (Fig. 4).
Fig. 4

Molecular cloning strategy of pCPD/ccdB

Use of pCPD increases expression and solubility fusion proteins

To more broadly investigate the applicability of this method, we utilized resources of the National Institute of Allergy and Infectious Diseases (NIAID) Center for Structural Genomics of Infectious Disease (CSGID,, which conducts HT cloning, protein production, and protein crystallization as an NIAID community resource. The next 40 CSGID target genes from this pipeline were selected to perform an unbiased pilot analysis of the impact the new pCPD vector could have on HT strategies. These 40 proteins include 36 unique bacterial proteins and 4 subdomains from 13 different species, although the majority (22 proteins) are proteins related to the type 2 secretion system (T2SS) from Klebsiella pneumoniae. The target genes were amplified by PCR, inserted into pCPD/ccdB, and expressed from the T7 promoter. As a control, the same fragments were cloned and expressed using pMCSG53/ccdB, a vector that expresses proteins fused to an TEV cleavable N-terminal 6x-His tag similar to pMCSG7 except that the plasmid also carries the rare tRNA codon genes ileX and argU (similar to pCPD/ccdB derived from pMCSG58) [16].

For all the recombinant proteins produced, the whole cell lysate and the supernatant fluid from induced cells were analyzed by SDS-PAGE and scored (Additional files 1 and 2). Twenty-eight (70%) of the CPD-fusion proteins were expressed when the genes were induced in E. coli compared to only 18 (45%) of those expressed with a TEV cleavable N-terminal 6xHis-tag (Fig. 5a). Sixteen HT targets were successfully expressed from both vectors, 12 were expressed exclusively from pCPD, while two were expressed exclusively from pMCSG53 (Fig. 5b). In terms of solubility, out of the 28 expressed CPD-fusions proteins, 24 (60%) were soluble, while 13 of the 18 expressed N-terminal 6xHis-tagged proteins were found in the supernatant fluid after lysis (Fig. 5b). In addition, three of the 16 proteins that were expressed from both plasmids were soluble only when expressed fused with CPD (Fig. 5b). Thus, the CPD functions not only as an easy strategy to remove a 6xHis-tag, but also enhances the success rate of protein expression and solubility.
Fig. 5

Expression and solubility of 40 bacterial proteins produced with pCPD and pMCSG53. a Percentage or b Number of expressed and soluble proteins resulting from expression of 40 selected target proteins from the indicated vector or vectors. n.d., not done

A major concern of the use of solubility tags is that proteins become insoluble upon tag removal. 16 of the 24 soluble CPD-fusions proteins were still soluble upon processing (Table 1). Thus, an HT strategy employing only pCPD would be expect to return 40% soluble proteins with tags removed. This is comparable or slightly better than an HT strategy dependent only on pMCSG53, which returned 33% (13/40) soluble proteins with the 6xHis-tag. Since removal of small 6xHis-tags does not generally result in protein insolubility, cleavage by TEV protease was not done and would not be expected to change this frequency. Of note, some proteins that were soluble from each vector were not the same (Additional file 2), such that an HT strategy that would employ both expression vectors in a side-by-side approach would be predicted to yield 53% soluble protein. Notably, since conducting this pilot, two structures deposited to PDB (ID 5DO8 [32] and 5F7S [33]) have been determined for proteins purified from pCPD, indicating that the presence of the 4 aa on the C-terminus does not interfere with crystallization. For these two proteins, CPD autoprocessing was performed at 4 °C overnight. This, together with previously tested conditions including 0.4 M urea [12], suggest that the removal of the CPD-tag can be achieved within a broad range of temperature from 4 °C to 37 °C and for different amount of time from 1 min to overnight without compromising the CPD activity.
Table 1

Summary of success frequencies in expression of 40 recombinant proteins in E. coli using two expression vectors, pCPD and pMCSG53a





Total target proteins







Expressed proteins in E. coli







Soluble proteins







Purified recombinant proteins





Soluble cleaved proteins






an.d., not done

bCombined soluble proteins expressed using pMCSG53 (uncleaved) and soluble cleaved proteins expressed using pCPD


In this work, a new vector, pCPD, was developed for overexpression of recombinant proteins with a C-terminal fusion to CPD-tag inducible by InsP6 to remove itself by autoprocessing. This new vector has several advantages over previous CPD-fusion vectors that depended on classical restriction enzyme gene insertion [8]. First, the backbone vector pMCGS58 provided a site for easy insertion of genes for protein expression by LIC or by recombination methods such as Gibson Assembly® and rare codons genes ileX and argU for improved success in protein expression. The pCPD vector was initially tested for two target proteins that had previously proven difficult to purify due to small size and insolubility, MLD and KRas, respectively. Interestingly, pCPD was shown to increase significantly the solubility of KRas1–169. Intrinsic and GAP stimulated GTP hydrolysis of KRas1–169-GAAL was equally active to KRas1–169 purified with an N-terminal 6xHis-tag. In addition, the developed purification protocol can be easily applied to a high yield-high purity, two-step production scale purification strategy of Ni-NTA followed by SEC. Strategies for single step purification and cleavage could also be developed and useful when protein yield and purity are not as essential as they are in structural determination and biochemical assessment.

The vector pCPD was then further modified to contain ccdB cassette in order to increase cloning efficiency. Using a pilot set of 40 proteins, the CPD-tag was unexpectedly shown to increase the rate of success for expression and solubility of recombinant proteins by 23% when compared with proteins expressed with a TEV protease cleavable 6xHis-tag. Thus, pCPD and pCPD/ccdB are excellent options both to be implemented as a first line approach to recombinant protein expression and solubility, or as a side-by-side alternative to standard TEV protease cleavable tags for successful recombinant protein production.



Hexahistidine tag


Coupled cell division B


Cysteine Protein Domain




Inositol hexaphosphate


Ligation-independent cloning


Multifunctional-Autoprocessing Repeats-in-Toxin


Membrane localization domain


Nickel-charged affinity resin


Size exclusion chromatography


Tobacco Etch Virus



DNA sequencing was conducted at the Northwestern Genomics Core.


This work was funded by the Northwestern Medicine Catalyst Fund (to K.J.F.S.) and by funds from NIAID, National Institutes of Health, Department of Health and Human Services, under Contract HHSN272201200026C (to W.F.A) and grants R01AI092825 and R01AI098369 (to K.J.F.S). M.B. was supported by a post-doctoral fellowship from the Pancreatic Cancer Action Network/National Cancer Institute.

Availability of data and material

All data generated or analyzed during this study are included in this published article and Additional files 1 and 2.

Authors’ contributions

MB, KJFS, and JSD designed and created the pCPD vector. MB tested the pCPD expression vector, developed purification strategies, and conducted biochemical characterization on Ras proteins. JW conducted solubility studies on Ras proteins. KK designed, created, and tested the pCPD/ccdB expression vector using the purified 40 target proteins. MB, KJFS, and KK wrote the manuscript. All authors read and approved the final manuscript.

Competing of interests

K.J.F.S holds patents related to use of CPD as tool in recombinant gene expression. M.B. and K.J.F.S. have submitted an addendum to this patent covering the pCPD vector. The remaining authors declare no competing financial interest.

Consent to publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University
Infectious Diseases Group, J. Craig Venter Institute
Center for Structural Genomics of Infectious Diseases, Feinberg School of Medicine, Northwestern University
Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University
Present address: Northwestern Memorial Hospital
Present address: Indiana University


  1. Aslanidis C, de Jong PJ. Ligation-independent cloning of PCR products (LIC-PCR). Nucleic Acids Res. 1990;18:6069–74.View ArticleGoogle Scholar
  2. Cabrita LD, Dai W, Bottomley SP. A family of E. coli expression vectors for laboratory scale and high throughput soluble protein production. BMC Biotechnol. 2006;6:12.View ArticleGoogle Scholar
  3. Eschenfeldt WH, Maltseva N, Stols L, Donnelly MI, Gu M, Nocek B, Tan K, Kim Y, Joachimiak A. Cleavable C-terminal His-tag vectors for structure determination. J Struct Funct Genomics. 2010;11:31–9.View ArticleGoogle Scholar
  4. Young CL, Britton ZT, Robinson AS. Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications. Biotechnol J. 2012;7:620–34.View ArticleGoogle Scholar
  5. Waugh DS. An overview of enzymatic reagents for the removal of affinity tags. Protein Expr Purif. 2011;80:283–93.View ArticleGoogle Scholar
  6. Panek A, Pietrow O, Filipkowski P, Synowiecki J. Effects of the polyhistidine tag on kinetics and other properties of trehalose synthase from Deinococcus geothermalis. Acta Biochim Pol. 2013;60:163–6.Google Scholar
  7. Perron-Savard P, De Crescenzo G, Le Moual H. Dimerization and DNA binding of the Salmonella enterica PhoP response regulator are phosphorylation independent. Microbiology. 2005;151:3979–87.View ArticleGoogle Scholar
  8. Shen A, Lupardus PJ, Morell M, Ponder EL, Sadaghiani AM, Garcia KC, Bogyo M. Simplified, enhanced protein purification using an inducible, autoprocessing enzyme tag. Plos One. 2009;4(12):e8119.View ArticleGoogle Scholar
  9. Satchell KJF. Cysteine protease autoprocessing of fusion proteins. U.S. Patent No. 8,257,946 B2. Sept. 4, 2012.Google Scholar
  10. Satchell KJF. Kits for producing recombinant polypeptides via cysteine protease autoprocessing of fusion proteins. U.S. Patent No. 8,383,400 B2. Feb. 26, 2013.Google Scholar
  11. Satchell KJ. Structure and function of MARTX toxins and other large repetitive RTX proteins. Annu Rev Microbiol. 2011;65:71–90.View ArticleGoogle Scholar
  12. Prochazkova K, Shuvalova LA, Minasov G, Voburka Z, Anderson WF, Satchell KJ. Structural and molecular mechanism for autoprocessing of MARTX toxin of Vibrio cholerae at multiple sites. J Biol Chem. 2009;284:26557–68.View ArticleGoogle Scholar
  13. Shen A, Lupardus PJ, Albrow VE, Guzzetta A, Powers JC, Garcia KC, Bogyo M. Mechanistic and structural insights into the proteolytic activation of Vibrio cholerae MARTX toxin. Nat Chem Biol. 2009;5:469–78.View ArticleGoogle Scholar
  14. Prochazkova K, Satchell KJ. Structure-function analysis of inositol hexakisphosphate-induced autoprocessing of the Vibrio cholerae multifunctional autoprocessing RTX toxin. J Biol Chem. 2008;283:23656–64.View ArticleGoogle Scholar
  15. Stols L, Gu M, Dieckman L, Raffen R, Collart FR, Donnelly MI. A new vector for high-throughput, ligation-independent cloning encoding a tobacco etch virus protease cleavage site. Protein Expr Purif. 2002;25:8–15.View ArticleGoogle Scholar
  16. Eschenfeldt WH, Makowska-Grzyska M, Stols L, Donnelly MI, Jedrzejczak R, Joachimiak A. New LIC vectors for production of proteins from genes containing rare codons. J Struct Funct Genomics. 2013;14:135–44.View ArticleGoogle Scholar
  17. Wu N, Christendat D, Dharamsi A, Pai EF. Purification, crystallization and preliminary X-ray study of orotidine 5’-monophosphate decarboxylase. Acta Crystallogr D Biol Crystallogr. 2000;56:912–4.View ArticleGoogle Scholar
  18. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009;6:343–U341.View ArticleGoogle Scholar
  19. Antic I, Biancucci M, Zhu Y, Gius DR, Satchell KJ. Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain. Nat Commun. 2015;6:7396.View ArticleGoogle Scholar
  20. Hobbs GA, Gunawardena HP, Baker R, Campbell SL. Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function. Small GTPases. 2013;4:186–92.View ArticleGoogle Scholar
  21. Gu H, Lalonde S, Okumoto S, Looger LL, Scharff-Poulsen AM, Grossman AR, Kossmann J, Jakobsen I, Frommer WB. A novel analytical method for in vivo phosphate tracking. FEBS Lett. 2006;580:5885–93.View ArticleGoogle Scholar
  22. Kwon K, Pieper R, Shallom S, Grose C, Kwon E, Do Y, Latham S, Alami H, Huang ST, Gatlin C, et al. A correlation analysis of protein characteristics associated with genome-wide high throughput expression and solubility of Streptococcus pneumoniae proteins. Protein Expr Purif. 2007;55:368–78.View ArticleGoogle Scholar
  23. Yu Y, Suh MJ, Sikorski P, Kwon K, Nelson KE, Pieper R. Urine sample preparation in 96-well filter plates for quantitative clinical proteomics. Anal Chem. 2014;86:5470–7.View ArticleGoogle Scholar
  24. Geissler B, Ahrens S, Satchell KJ. Plasma membrane association of three classes of bacterial toxins is mediated by a basic-hydrophobic motif. Cell Microbiol. 2012;14:286–98.View ArticleGoogle Scholar
  25. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–65.View ArticleGoogle Scholar
  26. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72:2457–67.View ArticleGoogle Scholar
  27. Abraham SJ, Muhamed I, Nolet R, Yeung F, Gaponenko V. Expression, purification, and characterization of soluble K-Ras4B for structural analysis. Protein Expr Purif. 2010;73:125–31.View ArticleGoogle Scholar
  28. Bernard P, Couturier M. Cell killing by the F plasmid CcdB protein involves poisoning of DNA-topoisomerase II complexes. J Mol Biol. 1992;226:735–45.View ArticleGoogle Scholar
  29. Geertsma ER, Dutzler R. A versatile and efficient high-throughput cloning tool for structural biology. Biochemistry. 2011;50:3272–8.View ArticleGoogle Scholar
  30. Walhout AJ, Temple GF, Brasch MA, Hartley JL, Lorson MA, van den Heuvel S, Vidal M. GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. Methods Enzymol. 2000;328:575–92.View ArticleGoogle Scholar
  31. Bernard P. Positive selection of recombinant DNA by CcdB. Biotechniques. 1996;21:320–3.Google Scholar
  32. Light SH, Halavaty AS, Anderson WF. 1.8 Angstrom crystal structure of Listeria monocytogenes Lmo0184 alpha-1,6-glucosidase, PDB ID: 5DO8, DOI: 2015.
  33. Light SH, Anderson WF. Cycloalternan-degrading enzyme from Trueperella pyogenes PDB ID: 5F7S DOI: 2015.


© The Author(s). 2017